Skip to main content

Advertisement

SpringerLink
Log in

Important drug–drug interactions for treatments that target overactive bladder syndrome

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Overactive bladder (OAB) is the term used to describe the symptom complex of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. It is a common distressing condition that significantly impairs quality of life (QoL). After lifestyle advice and bladder retraining, antimuscarinic drugs are most commonly used to treat OAB.

Methods

The antimuscarinics in common use are all metabolised through differing mechanisms. Therefore, the risk of an enhanced drug effect is increased when the potentially interacting substrates compete for the same metabolic pathways. The aim of this review is to provide an overview on potential drug–drug interactions with special emphasis on high-risk groups and clinically important consequences of these interactions

Results and Conclusion

Knowledge of current important drug interactions is vital whilst prescribing antimuscarinics, particularly in high-risk groups. Novel therapies, such as beta 3 agonists or alternative drug delivery systems, such as the oxybutynin vaginal ring, might provide alternative options where these interactions are unavoidable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri P, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26

    Article  PubMed  Google Scholar 

  2. Stewart WF, Corey R, Herzog AR et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 12(3):S66

    Google Scholar 

  3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766

    Article  CAS  PubMed  Google Scholar 

  4. Sibley GN (1997) Developments in our understanding of overactive bladder. Br J Urol 80:54–61

    PubMed  Google Scholar 

  5. Brading AF (1997) A myogenic basis for the overactive bladder. Urology 50:57–67

    Article  CAS  PubMed  Google Scholar 

  6. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ (2009) Pharmacological treatment of urinary incontinence. In: Incontinence, 4th edition. Abrams P, Cardozo L, Khoury S, Wein A (eds) Health Publications, Editions 21, Paris, pp 631–700

  7. 5th International Consultation on Incontinence meeting, Paris, France, February 2012

  8. Harbour R, Miller J (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323:334–336

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65(5):567–585

    Article  CAS  PubMed  Google Scholar 

  10. Oefelein MG (2011) Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 34(9):733–754

    Article  CAS  PubMed  Google Scholar 

  11. Paquette A, Gou P, Tannenbaum C(2011) Systematic review and meta-analysis; do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 1332–1339.

  12. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J (2009) Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin. Expert Opin Drug Saf 8:615–626

    Article  CAS  PubMed  Google Scholar 

  13. Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62:1792–1800

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Staskin D, Kay G, Tannebaum C, Goldman HB, Bhashi K, Ling J, Oefelein MG (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294–1300

    Article  CAS  PubMed  Google Scholar 

  15. Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, Ferrero S (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol 8(11):1387–1408

    Article  PubMed  Google Scholar 

  16. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211–2221

    Article  CAS  PubMed  Google Scholar 

  17. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7:41–53

    Article  CAS  PubMed  Google Scholar 

  18. Deeken JF, Loscher W (2007) The blood–brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663–1674

    Article  CAS  PubMed  Google Scholar 

  19. Pak RW, Petrou SP, Staskin DR (2003) Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 4:436–440

    Article  PubMed  Google Scholar 

  20. Sandage B, Lerch G, Larsen G, Profy A (2009) Trospium chloride does not cross the blood–brain barrier of male Long Evans rats. Neurology 72 [Suppl 3]:A50

    Google Scholar 

  21. Wagg A (2006) Managing special populations: the elderly. Eur Urol Suppl 5:866–870

    Article  Google Scholar 

  22. Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167–174

    Article  CAS  PubMed  Google Scholar 

  23. Wagg A (2012) The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev 7:42–49

    Google Scholar 

  24. Zipser BD, Johanson CE, Gonzalez L et al (2007) Microvascular injury and blood–brain barrier leakage in Alzheimer’s disease. Neurobiol Aging 28:977–986

    Article  CAS  PubMed  Google Scholar 

  25. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I (2003) Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 74:70–76

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Wagg A (2011) Treating overactive bladder in the elderly. Can Urol Assoc J 5 [Suppl 2]:S149–S151

    Article  PubMed Central  PubMed  Google Scholar 

  27. McKeage K (2013) Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig 33(1):71–91

    Article  CAS  PubMed  Google Scholar 

  28. Bolduc S, Upadhyay J, Payton J et al (2003) The use of tolterodine in children after oxybutynin failure. BJU Int 91:398–401

    Article  CAS  PubMed  Google Scholar 

  29. Yucel S, Akkaya E, Guntekin E et al (2005) Should we switch over to tolterodine in every child with nonneurogenic daytime urinary incontinence in whom oxybutynin failed? Urology 65:369–373

    Article  PubMed  Google Scholar 

  30. Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M (2010) Prospective open label study of solifenacin for overactive bladder in children. J Urol 184 [4 Suppl]:1668–1673

    Article  PubMed  Google Scholar 

  31. Lopez Pereira P, Miguelez C, Caffarati J, Estornell F, Anguera A (2003) Trospium chloride for the treatment of detrusor instability in children. J Urol 170(5):1978–1981

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Conflict of interest

Sushma Srikrishna—speaker honorarium: Recordati; consultant: Astellas; travel grant to attend ICS: Boston Scientific, Recordati. Dudley Robinson—consultant: Astellas, Pfizer, Gyanecare, Ferring; speaker honorarium: Astellas, Pfizer and Gynaecare; meeting expenses from Astellas and Pfizer. Linda Cardozo—consultant: Allergan, Astellas, Pfizer, Teva; speaker honorarium: Astellas, Pfizer; trial participation: Astellas, Pfizer; research grant: Pfizer.

Author information

Authors and Affiliations

  1. Department of Urogynaecology, King’s College Hospital, Denmark Hill, London, SE5 9RS, UK

    Sushma Srikrishna, Dudley Robinson & Linda Cardozo

Authors
  1. Sushma Srikrishna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dudley Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda Cardozo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sushma Srikrishna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srikrishna, S., Robinson, D. & Cardozo, L. Important drug–drug interactions for treatments that target overactive bladder syndrome. Int Urogynecol J 25, 715–720 (2014). https://doi.org/10.1007/s00192-013-2259-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-013-2259-8

Keywords

Search

Navigation